History of Hologic in Timeline

Hologic, Inc. is a U.S.-based medical technology company specializing in women's health. They develop and sell medical devices used in diagnostics, surgery, and medical imaging, with a focus on addressing various health needs specific to women.

November 2013: Carl Icahn Discloses Stake

In November 2013, activist investor Carl Icahn disclosed a 12.5% stake in Hologic, leading the company to adopt a poison pill to prevent a hostile takeover.

March 3, 2016: Icahn Nominees Resign

On March 3, 2016, Carl Icahn's nominees to Hologic's board of directors resigned.

May 16, 2016: Icahn Exits Position

On May 16, 2016, Carl Icahn exited his position in Hologic, considering his investment and intervention a success.

2017: Acquisition of Cynosure

In 2017, Hologic acquired Cynosure, an aesthetic medicine company based in Westford, Massachusetts, for $1.65 billion.

November 20, 2019: Divestment of Cynosure Announced

On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million.

December 30, 2019: Divestment of Cynosure Completed

On December 30, 2019, Hologic completed the divestment of Cynosure to Clayton, Dubilier & Rice. Cynosure had approximately 825 employees at the time.

2019: Second Emergency Use Authorization

In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.

March 2020: Emergency Use Authorization for SARS-CoV-2 Test

In March 2020, Hologic received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic.

May 2020: Second Emergency Use Authorization

In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.

June 2020: Collaboration with Grifols

In June 2020, Hologic collaborated with Grifols to increase Spain's testing capacity for COVID-19.

November 2020: $119 Million Contract for COVID Test Expansion

In November 2020, Hologic won a $119 million contract from the U.S. Department of Health and Human Services and the Department of Defense to expand production facilities in Wisconsin, Maine, and California.

January 2021: Acquisition of Biotheranostics and SOMATEX

In January 2021, Hologic announced it would acquire Biotheranostics and its breast and metastatic cancer test portfolio for $230 million and SOMATEX for $64 million.

April 2021: Acquisition of Mobidiag Announced

In April 2021, Hologic announced it will acquire Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.

June 2021: Acquisition of Mobidiag Completed

The acquisition of Mobidiag, which was announced in April 2021, completed in June 2021.

January 2022: Goal to Provide 13 Million COVID Tests Per Month

By January 2022, Hologic aimed to provide 13 million COVID tests per month as part of the $119 million contract won in November 2020.

March 2022: Title Sponsor of WTA Tour

In March 2022, Hologic became the title sponsor of the WTA Tour in women's professional tennis and was named the "official health partner" of the Women's Tennis Association.